Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
LW
LightWave Acquisition Corp. Class A Ordinary Shares
LWAC
Volume
110
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
LW
LWAC
LW
LightWave Acquisition Corp. Class A Ordinary Shares
LWAC
News
·
Why Is This SPAC Surging 160% Today?
Mkt Cap
$311.3M
Volume
110
Next Earnings
N/A
Chart
Earnings
News
About
Insider
Filings
Why Is This SPAC Surging 160% Today?
Shares of Locust Walk Acquisition Corp (NASDAQ: LWAC) are surging higher Wednesday morning after the merger with eFFECTOR Therapeutics was approved. eFFECTOR Therapeutics is focused on selective translation regulation inhibitors to treat cancer. The SPAC merger valued the company at $419 million, including a $60 million PIPE with an investment from Pfizer Inc's (NYSE: PFE) venture capital arm Pfizer Ventures. Related Link: Exclusive: Accelerate CEO On SPAC Arbitrage, Why You Can't Always Bet On SPAC Sponsor Why The Stock Is Soaring: Locust Walk Acquisition raised $175 million in its IPO, selling 17.5 ...
Benzinga · Aug 25, 2021
EXCLUSIVE: eFFECTOR, Locust Walk Acquisition CEOs On SPAC Deal, Drug Pipeline
Clinical-stage biopharmaceutical company eFFECTOR Therapeutics is set to go public via the special purpose acquisition company Locust Walk Acquisition Corp (NASDAQ: LWAC) with an enterprise value of $419 million. Steve Worland, the president and CEO of eFFECTOR, and Chris Ehrlich, CEO of Locust Walk Acquisition Corp., appeared on Benzinga's YouTube show "SPACs Attack" for an exclusive interview Wednesday. eFFECTOR Programs: eFFECTOR focuses on using a new class of oncology drugs known as selective translation regulation inhibitors to treat cancer. eFFECTOR has a global partnership with Pfizer Inc (NYSE: PFE) for the development of inhibitors of eIF4E, which is the company's earliest stage program, Worland told Benzinga. Tomivosertib, which targets non-small cell lung cancer, is in late-stage Phase 2 trials and is the furthest along of eFFECTOR's programs, he said, adding ...
Benzinga · Jun 23, 2021
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
LW
LWAC
LightWave Acquisition Corp. Class A Ordinary Shares
Buy
Sell
Market
Limit
Soon
LWAC
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any LWAC yet.
Related Tickers
Earnings